Skip to main content

Table 9 Recommendations for follow-up

From: Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net

Test

Frequency

Grade

SS-LCH And No Disease Activity

History (especially of thirst, polyuria, cough, dyspnea, bone pain, skin changes, neurological symptoms)

• Every clinic visit

D2

Clinical assessment, blood count and blood chemistry (as described in baseline diagnostics), ultrasound

• End of therapy

D2

• every 6 month (for the next 2 years)

• then once a year (for at least 3 years)

Chest XR

• annually (for at least 3 years)

D2

After MS-LCH And With No Disease Activity

History (especially of thirst, polyuria, cough, dyspnea, bone pain, skin changes, neurological symptoms)

• Every clinic visit

D2

Clinical assessment, blood count and blood chemistry (as described in baseline diagnostics), ultrasound

• End of therapy

D2

• every 3 month (for the next 2 years)

• every 6 month (for the next 3 years)

• then once a year (for at least 5 years)

Chest XR

• annually (for at least 3 years)

D2

TSH, freeT4

• Once a year (until end of routinely follow up)

D2

Patients With Active Disease

Diagnostic procedures are depending on the site of organ involvement

Frequency is depending on rates and velocity of recurrences

D2

Patients With pLCH

History (in case of non-pulmonary symptoms: look for MS LCH, see Table 4)

• Every clinic visit

D2

Diagnostic procedures are depending on symptoms und course of PLCH (baseline: Chest X-ray, lung function (+DCLO)

• End of therapy

D2

• every 6 month (for the next 2 years)

• then once a year (for at least 5 years)